[
  {
    "ts": "2026-02-12T01:22:00+00:00",
    "headline": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
    "summary": "SANTA CLARA, Calif., February 12, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
    "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
      "content": {
        "id": "f1e04c13-ee6a-337d-bb05-8f200b17e962",
        "contentType": "STORY",
        "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)",
        "description": "",
        "summary": "SANTA CLARA, Calif., February 12, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.",
        "pubDate": "2026-02-12T01:22:00Z",
        "displayTime": "2026-02-12T01:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad",
          "originalWidth": 1000,
          "originalHeight": 404,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PQWewlSpOjq3LBzkeZ9umg--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 1000,
              "height": 404,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W0iu6UMRdyYDW2qH3YUL1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agilent-receives-fda-approval-pd-114500053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-12T11:10:35+00:00",
    "headline": "Merck’s Ovarian Cancer Wins Tested Against Valuation Gap And Momentum",
    "summary": "Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its subcutaneous formulation QLEX for platinum-resistant ovarian cancer. The FDA also approved a companion diagnostic to help identify patients who may benefit from these treatments. Merck announced an industry partnership to support development of an intravaginal drug delivery platform, expanding its women's health efforts. With shares at $119.31, NYSE:MRK trades against a backdrop of multi period gains of 12.1% year to date and 44.5%...",
    "url": "https://finance.yahoo.com/news/merck-ovarian-cancer-wins-tested-111035434.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3df36121-725a-3524-ab2e-c4428439b471",
      "content": {
        "id": "3df36121-725a-3524-ab2e-c4428439b471",
        "contentType": "STORY",
        "title": "Merck’s Ovarian Cancer Wins Tested Against Valuation Gap And Momentum",
        "description": "",
        "summary": "Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its subcutaneous formulation QLEX for platinum-resistant ovarian cancer. The FDA also approved a companion diagnostic to help identify patients who may benefit from these treatments. Merck announced an industry partnership to support development of an intravaginal drug delivery platform, expanding its women's health efforts. With shares at $119.31, NYSE:MRK trades against a backdrop of multi period gains of 12.1% year to date and 44.5%...",
        "pubDate": "2026-02-12T11:10:35Z",
        "displayTime": "2026-02-12T11:10:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-ovarian-cancer-wins-tested-111035434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-ovarian-cancer-wins-tested-111035434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]